Research progress on pathogenesis and individualized treatment in patients with eosinophilic chronic obstructive pulmonary disease

WANG Yalin; YI Chuanhua; ZHU Muyun

doi:10.7619/jcmp.20211345

Journal of Clinical Medicine in Practice > 2021 > 25(18): 128-132. > DOI: 10.7619/jcmp.20211345

WANG Yalin, YI Chuanhua, ZHU Muyun. Research progress on pathogenesis and individualized treatment in patients with eosinophilic chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 128-132. DOI: 10.7619/jcmp.20211345

Citation:

PDF (623 KB)

Research progress on pathogenesis and individualized treatment in patients with eosinophilic chronic obstructive pulmonary disease

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, 225001

More Information

Received Date: March 26, 2021
Available Online: October 19, 2021
Published Date: September 27, 2021

Graphical Abstract

Abstract

Abstract

In recent years, eosinophil (EOS) has attracted much attention in the treatment of chronic obstructive pulmonary disease (COPD). Some COPD patients are observed with active airway inflammation and systemic inflammation, increase of circulating EOS, and a variety of involved inflammatory markers. At present, the relationship between EOS threshold and clinical treatment of COPD is still controversial, but EOS count has been used as a biomarker in clinical practice, especially in COPD patients gaining benefits of improving the prognosis and preventing the deterioration of the disease after inhaling corticosteroids. In addition, a variety of treatment methods for eosinophilic inflammation have been or are being researched and developed, including monoclonal antibodies against inflammatory mediators such as interleukin, chemokines and their receptors. This paper reviewed the biological characteristics of EOS, its role in the pathogenesis of COPD and its value as a biomarker in decision-making of individualized treatment.
- eosinophils,
- chronic obstructive pulmonary disease,
- glucocorticoids,
- targeted therapy,
- chemokines,
- activating factor

FullText(HTML)

References (38)

References

[1]	陈亚红. 2020年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志: 电子版, 2019, 11(12): 32-50. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY201912010.htm
[2]	TWOREK D, ANTCZAK A. Eosinophilic COPD—a distinct phenotype of the disease[J]. Adv Respir Med, 2017, 85(5): 271-276. doi: 10.5603/ARM.a2017.0045
[3]	NEGEWO N A, MCDONALD V M, BAINES K J, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 1495-1504. doi: 10.2147/COPD.S100338
[4]	CAO Y, GONG W, ZHANG H, et al. A Comparison of Serum and Sputum Inflammatory Mediator Profiles in Patients with Asthma and COPD[J]. Journal of International Medical Research, 2012, 40(6): 2231-2242. doi: 10.1177/030006051204000621
[5]	SINGH D, KOLSUM U, BRIGHTLING C E, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics[J]. Eur Respir J, 2014, 44(6): 1697-1700. doi: 10.1183/09031936.00162414
[6]	LANDIS S H, SURUKI R, HILTON E, et al. Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink[J]. COPD, 2017, 14(4): 382-388. doi: 10.1080/15412555.2017.1313827
[7]	GEORGE L, BRIGHTLING C E. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease[J]. Ther Adv Chronic Dis, 2016, 7(1): 34-51. doi: 10.1177/2040622315609251
[8]	BAFADHEL M, MCCORMICK M, SAHA S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease[J]. Respiration, 2012, 83(1): 36-44. doi: 10.1159/000330667
[9]	SAETTA M, DI STEFANO A, MAESTRELLI P, et al. Airway eosinophilia in chronic bronchitis during exacerbations[J]. Am J Respir Crit Care Med, 1994, 150(6 Pt 1): 1646-1652.
[10]	TASHKIN D P, WECHSLER M E. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 335-349. doi: 10.2147/COPD.S152291
[11]	BALZANO M, DE GRANDIS M, VU MANH T P, et al. Nidogen-1 contributes to the interaction network involved in pro-B cell retention in the peri-sinusoidal hematopoietic stem cell niche[J]. Cell Rep, 2019, 26(12): 3257-3271,e8. doi: 10.1016/j.celrep.2019.02.065
[12]	KOLSUM U, RAVI A, HITCHEN P, et al. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma[J]. Respir Res, 2017, 18(1): 73. doi: 10.1186/s12931-017-0559-0
[13]	PASCOE S, BARNES N, BRUSSELLE G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial[J]. Lancet Respir Med, 2019, 7(9): 745-756. doi: 10.1016/S2213-2600(19)30190-0
[14]	KERKHOF M, VOORHAM J, DORINSKY P, et al. Association between COPD exacerbations and lung function decline during maintenance therapy[J]. Thorax, 2020, 75(9): 744-753. doi: 10.1136/thoraxjnl-2019-214457
[15]	WHITTAKER H R, MVLLEROVA H, JARVIS D, et al. Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1063-1073. doi: 10.2147/COPD.S200919
[16]	MATHIOUDAKIS A G, BIKOV A, FODEN P, et al. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD[J]. Eur Respir J, 2020, 55(5): 1902119. doi: 10.1183/13993003.02119-2019
[17]	BAFADHEL M, DAVIES L, CALVERLEY P M A, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis[J]. Eur Respir J, 2014, 44(3): 789-791. doi: 10.1183/09031936.00062614
[18]	BRIGHTLING C, GREENING N. Airway inflammation in COPD: progress to precision medicine[J]. Eur Respir J, 2019, 54(2): 1900651. doi: 10.1183/13993003.00651-2019
[19]	MKOROMBINDO T, DRANSFIELD M T. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease[J]. Int J Chronic Obstr Pulm Dis, 2019, 14: 1779-1787. doi: 10.2147/COPD.S162781
[20]	PAVORD I D, CHANEZ P, CRINER G J, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease[J]. N Engl J Med, 2017, 377(17): 1613-1629. doi: 10.1056/NEJMoa1708208
[21]	FERNANDEZ ROMERO G A, BEROS J, CRINER G. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations[J]. Expert Rev Respir Med, 2019, 13(2): 125-132. doi: 10.1080/17476348.2019.1561287
[22]	HASSANI M, KOENDERMAN L. Immunological and hematological effects of IL-5(Rα)-targeted therapy: an overview[J]. Allergy, 2018, 73(10): 1979-1988. doi: 10.1111/all.13451
[23]	NIXON J, NEWBOLD P, MUSTELIN T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation[J]. Pharmacol Ther, 2017, 169: 57-77. doi: 10.1016/j.pharmthera.2016.10.016
[24]	BRIGHTLING C E, BLEECKER E R, PANETTIERI R J, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study[J]. Lancet Respir Med, 2014, 2(11): 891-901. doi: 10.1016/S2213-2600(14)70187-0
[25]	CRINER G J, CELLI B R, SINGH D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies[J]. Lancet Respir Med, 2020, 8(2): 158-170. doi: 10.1016/S2213-2600(19)30338-8
[26]	FAJT M L, WENZEL S E. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care[J]. J Allergy Clin Immunol, 2015, 135(2): 299-311. doi: 10.1016/j.jaci.2014.12.1871
[27]	KIM S W, RHEE C K, KIM K U, et al. Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 395-402. doi: 10.2147/COPD.S120445
[28]	DOYLE A D, MUKHERJEE M, LESUER W E, et al. Eosinophil-derived IL-13 promotes emphysema[J]. Eur Respir J, 2019, 53(5): 1801291. doi: 10.1183/13993003.01291-2018
[29]	EICKMEIER O, HUEBNER M, HERRMANN E, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function[J]. Cytokine, 2010, 50(2): 152-157. doi: 10.1016/j.cyto.2010.02.004
[30]	PANETTIERI R A Jr, SJÖBRING U, PÉTERFFY A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials[J]. Lancet Respir Med, 2018, 6(7): 511-525. doi: 10.1016/S2213-2600(18)30184-X
[31]	KAUR D, GOMEZ E, DOE C, et al. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk[J]. Allergy, 2015, 70(5): 556-567. doi: 10.1111/all.12593
[32]	SHANG J, ZHAO J L, WU X J, et al. Interleukin-33 promotes inflammatory cytokine production in chronic airway inflammation[J]. Biochimie et Biol Cell, 2015, 93(4): 359-366. doi: 10.1139/bcb-2014-0163
[33]	JACKSON D J, MAKRINIOTI H, RANA B M, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo[J]. Am J Respir Crit Care Med, 2014, 190(12): 1373-1382. doi: 10.1164/rccm.201406-1039OC
[34]	UCHIMIZU H, MATSUWAKI Y, KATO M, et al. Eosinophil-derived neurotoxin, elastase, and cytokine profile in effusion from eosinophilic otitis media[J]. Allergol Int, 2015, 64(Suppl): S18-S23.
[35]	RABE K F, WATZ H, BARALDO S, et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial[J]. Lancet Respir Med, 2018, 6(11): 827-836. doi: 10.1016/S2213-2600(18)30331-X
[36]	MARTINEZ F J, RABE K F, CALVERLEY P M A, et al. Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. pooled analysis of two randomized trials[J]. Am J Respir Crit Care Med, 2018, 198(10): 1268-1278. doi: 10.1164/rccm.201712-2493OC
[37]	王红梅, 刘耘充, 郑丹蕾, 等. 血嗜酸性粒细胞作为生物标志物在慢性阻塞性肺疾病中的研究进展[J]. 中华全科医学, 2020, 18(5): 815-820. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202005032.htm
[38]	JACKSON D J, KORN S, MATHUR S K, et al. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab[J]. Drug Safety, 2020, 43.

[1]	WANG Ping, LIU Jianrong, YU Lei, MA Lifen, ZHAO Lili. Correlations of serum stromal cell-derived factor-1, chemokine receptor 7 and vascular density in the optic disc area with clinical stages in patients with normal-tension glaucoma[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 1-5. DOI: 10.7619/jcmp.20244420
[2]	GU Jianguo, NI Jie, SI Guojun. Correlation of serum B-cell activating factor level with cardiovascular events in patients with ST segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 52-56. DOI: 10.7619/jcmp.20233732
[3]	QIN Lei, QIN Xin. Myeloid differentiation factor 88 regulates the proliferation, migration and invasion of colorectal cancer cells through the nuclear factor-κB/activator protein-1 signaling pathway[J]. Journal of Clinical Medicine in Practice, 2023, 27(14): 40-45. DOI: 10.7619/jcmp.20223737
[4]	GU Fengjuan, XU Zibin, XU Yunpeng, ZHANG Yanzi, LI Lixiang, SUI Xiaolu, ZOU Jiefeng, ZENG Qicheng, XIE Tingfei, CHEN Jihong. Mechanism of Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in model micewith focal segmental glomerulosclerosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(21): 74-79. DOI: 10.7619/jcmp.20222730
[5]	YUAN Hongli, WANG Xian, WANG Xiumei, ZHOU Yu. Clinical significance of angiogenin protein 4, interleukin-17 and nuclear factor-kappa B ligand in serum and articular fluid of patients with rheumatoid arthritis[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 57-62. DOI: 10.7619/jcmp.20220103
[6]	LIAO Dongsheng, A Huaihong, LI Shaohua, GAO Chunyuan, SHEN Jun, WANG Hongjun. Changes of serum adropin, platelet activating factor and glial fibrillary acidic protein levels in patients with coronary heart disease complicating depression and their significance[J]. Journal of Clinical Medicine in Practice, 2021, 25(24): 74-77, 82. DOI: 10.7619/jcmp.20212667
[7]	YU Dongqing, CHE Lu. Analysis of the relationships between CD62p, CD63 as well as platelet activating factor expression and clinical prognosis in patients with acute ischemic cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(19): 36-38. DOI: 10.7619/jcmp.20212694
[8]	WANG Qi, ZHOU Xiangdong, HAN Zhong, LIU Chang. Effects of expression of activator protein-1 and polytumour activator in tissue of non-small cell lung cancer on prognosis[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 1-5. DOI: 10.7619/jcmp.20201847
[9]	LIU Benhong, ZHOU Ning, SUN Mingxiang, YU Jia, GAO Songfeng. The effect of inhaled glucocorticoid therapy on levels of cytokines in serum and sputum of patients with acute exacerbation of the chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2016, (11): 32-34,46. DOI: 10.7619/jcmp.201611010
[10]	LUO Bei-hai. Influence of clopidogrel on the levels of plasma inflammatory factor and platelet activating factor in patients with unstable angina[J]. Journal of Clinical Medicine in Practice, 2012, (7): 75-77. DOI: 10.3969/j.issn.1672-2353.2012.07.024

Cited By

Cited by

Periodical cited type(11)

1.	牛绍迁，杨魏东，冯灵，张晓瑶，周琼蓉. 老年卒中后睡眠障碍的影响因素及药物与非药物治疗研究进展. 保健医学研究与实践. 2024(03): 134-138 .
2.	史哲宇，黄慧丽，朱少炳，朱路文. 近5年血府逐瘀汤在神经系统疾病中的应用及作用机制研究进展. 中医药学报. 2024(11): 109-114 .
3.	张雯，江丽杰，赵海河. 《医林改错》中活血化瘀类方剂治疗中风的研究进展. 中国中医基础医学杂志. 2023(06): 1036-1039 .
4.	高娟，张则甫. 血府逐瘀汤联合康复训练对脑卒中后偏瘫足下垂患者下肢肌张力恢复及体感诱发电位的影响. 中国民族医药杂志. 2023(11): 8-10 .
5.	孙晓. 血府逐瘀胶囊辅治脑卒中后抑郁临床观察. 实用中医药杂志. 2023(12): 2418-2420 .
6.	乔煦，吴广，王钰. 养心方对缺血性脑卒中后睡眠障碍患者睡眠质量及血清5-HT、BDNF水平的影响. 中医药信息. 2022(02): 60-63 .
7.	路琦，张永全. 中西医治疗脑卒中后失眠的研究进展. 大众科技. 2022(02): 106-109+113 .
8.	贾军. 清肺化痰逐瘀汤治疗冠心病临床观察. 光明中医. 2022(08): 1423-1425 .
9.	沈晓桦，卢根娣，蒋国静，胡丽，谈晓红. 引阳入阴推拿对剖宫产后心脾两虚证产妇睡眠障碍及负性情绪的影响. 实用临床医药杂志. 2022(09): 54-58 . 本站查看
10.	陈素银. 血府逐瘀汤对缺血性脑卒中患者血清细胞因子水平和脑血流的影响. 光明中医. 2022(13): 2357-2359 .
11.	徐梦圆，孙平，杨言府. 血府逐瘀汤联合小剂量奥氮平治疗脑卒中后睡眠障碍30例临床观察. 中国民族民间医药. 2022(23): 113-115+118 .

Other cited types(3)

Get Citation

PDF

XML

Article views (308) PDF downloads (39) Cited by(14)

Turn off MathJax

Article Contents

Abstract

References

Research progress on pathogenesis and individualized treatment in patients with eosinophilic chronic obstructive pulmonary disease

Abstract

References

Related Articles

Cited by

Periodical cited type(11)

Other cited types(3)

Catalog

Research progress on pathogenesis and individualized treatment in patients with eosinophilic chronic obstructive pulmonary disease

Abstract

References

Related Articles

Cited by

Periodical cited type(11)

Other cited types(3)

Catalog

Export File

Citation

Format

Content